Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Agentix Signs WW Licensing Agreement for T2DM, NAFLD, and Obesity Asset

Here is a brief preview of this blast: Agentix announced it has entered into a WW exclusive license and technology transfer agreement with the National Health Research Institutes (NHRI) of Taiwan ROC. According to the press release, Agentix will license several NHRI patents and patent applications to develop, manufacture, and commercialize DBPR211 for the treatment of human disease. For context, DBPR211 is a peripherally restricted cannabinoid receptor 1 antagonist that has completed preliminary pre-clinical and in vivo testing requirements. Agentix intends to begin Ph1 trials by September 2022. Below, FENIX provides context and insights for the announcement.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.